NEXTEK-LTD
24.3.2021 09:33:11 CET | Business Wire | Press release
Following eight years extensive research, Nextek Ltd has launched a global multi-participant project (NEXTLOOPP) to address a missing link in the plastics recycling stream - Polypropylene (PP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005370/en/
PP accounts for around 20 percent of the world’s plastic.1 Mostly used in pots, tubs, trays and films for food packaging, it is also prevalent in non-food household and personal care products, which complicates recycling the 700,000 tonnes/annum used in the UK alone.2
Currently PP packaging is either going to waste-to-energy, landfill or being down-cycled into low-performance applications, wasting precious resources. Furthermore, the absence of food-grade recycled PP (FGrPP) means that all PP food packaging is currently made from virgin plastics.
Looming plastic packaging taxes have sharpened a focus on including at least 30 percent recycled content in packaging and transforming the way we manage our short-lived materials to minimise and reduce current waste levels.
NEXTLOOPP uses commercially-proven technologies to separate food-grade PP using marker technologies. These include cutting-edge decontamination stages to ensure compliance with food-grade standards in the EU and the USA. Now we can finally close the loop on FGrPP.
Major organisations including brand-owners, suppliers, universities and industry associations, through to end-users in the PP supply chain, have joined NEXTLOOPP to produce a world-first; high-quality FGrPP that will be available in the UK by 2022.
Professor Edward Kosior, founder and CEO of Nextek Ltd, explains that creating a circular economy for food-grade PP packaging waste fills the enormous gap in the packaging recycling sector and helps reach Net Zero Carbon targets. “It will allow brand owners to meet their recycling targets and significantly reduce the use of virgin plastics from petrochemicals. It will also greatly reduce CO2 emissions and divert waste from landfill and waste-to-energy.”
UK-based WRAP has confirmed that The UK Plastics Pact is pleased to support the NEXTLOOPP project in delivering a technology that will achieve food-grade polypropylene. WRAP’s Acting Director Insights and Innovation, Claire Shrewsbury, says that finding a way to successfully recycle food-contact polypropylene is a key challenge. “Achieving this will enable UK Plastics Pact members to reach the target of an average of 30 percent recycled content across all packaging by 2025. WRAP believes that NEXTLOOPP offers a potential solution to this and we will work closely with the other stakeholders to develop the project further.”
Viridor’s Director of Business Development (Polymers), Luke Burgess, says the company’s participation in the food-grade trial is in line with Viridor’s ongoing commitment to the UK circular economy. ”Viridor believes that extending its polymers expertise and recycling experience to cross-sector collaboration and innovation is key to ensuring more waste is valued as a resource and returns to the circular economy where it belongs. Reducing our reliance on virgin plastic not only empowers greater circularity, but the continued use of recycled material also offers significant energy savings, contributing to considerable wider environmental benefits for the UK.”
Lubna Edwards, Group Sustainability and Marketing Director at Robinson Packaging says: “NEXTLOOPP is absolutely aligned with Robinson’s goals and those of our customers for closed-loop solutions, as well as governmental circular economy targets. Demand for this high-value recycled material will continue to rise as we shift away from using virgin material. Much of our UK business depends upon PP and this ground-breaking project gives us the opportunity to tap into cutting-edge technology, learn from industry partners and trial the material for sustainable use in our packaging.”
Andrew Fisher, Managing Director of leading plastic packaging manufacturer Sharpak Yate, says: “As part of the Guillin Group, Sharpak has recyclability in its DNA. NEXTLOOPP is an industry-leading initiative and we are proud to be collaborating with this multi-participant project.”
Adam Elman, Group Sustainability Director at Klöckner Pentaplast says: “Capturing the value of plastics by keeping them within the economy and out of our natural environment is key to meeting the Plastics Pact targets and very much part of our business strategy. Swapping the traditional ‘take-make-waste’ linear model for a circular system is also one of the many important steps towards significantly reducing our carbon emissions. We are proud to be working in collaboration with NEXTLOOPP on this important project.”
As of 23 March 2021, 29 organisations across the PP supply chain have joined NEXTLOOPP. Other multinational companies are soon to join.
About Nextek Ltd
Nextek is a global sustainability consultancy that offers strategic advice to regional and multi-national organisations and recycling companies. Launched in 2004, Nextek researches and develops innovative strategies and processes within the recycling ecosystem – from designing recycling plants to developing ground-breaking projects for governments and major organisations. Nextek launched NEXTLOOPP, a two-year multi-participant project, to close the loop on food-grade rPP. This project incorporates unique technological breakthroughs that include innovative sorting and cutting-edge decontamination technology.
- WRAP (www.wrap.org.uk ): PlasticFlow 2025 – Plastic Packaging Flow Data Report. August 2018
- PlasticsEurope Market Research Group (www.plasticseurope.org/en/resources/publications/4312-plastics-facts-2020 ): AF_Plastics_the_facts-WEB-2020-ING_FINAL.PDF; Slides 23 & 25.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005370/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
